Compare Enveric Biosciences Inc (ENVB) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Diamondback Energy Inc — how do they compare? Enveric Biosciences Inc trades at $1.6 (market cap $6.20M), while Diamondback Energy Inc trades at $200.15 (market cap $56.48B). The key difference: Diamondback Energy Inc is far larger — about 9109.7× Enveric Biosciences Inc's market cap, and Diamondback Energy Inc pays a 2.18% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | FANG | |
|---|---|---|
Market Cap | $6.20M | $56.48B |
Sector | Health | Energy |
52-Week High | $17.40 | $213.69 |
52-Week Low | $1.27 | $134.53 |
Enterprise Value | $1.30M | $68.63B |
Dividend Yield | — | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.56, up 1.3% on the day, with a bullish technical signal from moving averages and strong analyst support (75% buy ratings). The company reported four consecutive quarterly earnings beats in 2025, including a positive EPS of $0.85 in Q4, while recent news highlights progress in preclinical studies for its non-hallucinogenic psychiatric drug candidate EB-003.
Despite operational losses and negative ROE/ROA, ENVB's consistent earnings surprises and advancing pipeline present speculative growth potential. Key risks include cash burn, clinical trial outcomes, and regulatory hurdles, requiring careful risk assessment by investors.
Diamondback Energy (FANG) trades at $198.97, up 5.81% with strong Q2 2026 earnings beating estimates. Technical indicators show bullish momentum with support at $193 and resistance at $202. Revenue grew to $14.93B in 2025, though profit margins compressed to 11.14%. Analyst consensus is strongly bullish with a $236.63 price target and 90% buy ratings.
FANG offers growth potential through production increases and debt reduction, supported by elevated oil prices. Risks include commodity price volatility and margin pressure from rising costs. The stock trades at a premium P/E of 38.42 but remains attractive given operational efficiency gains and institutional accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
